Citigroup Lowers Integra LifeSciences (NASDAQ:IART) Price Target to $9.00

Integra LifeSciences (NASDAQ:IART) had its price objective reduced by stock analysts at Citigroup from $11.00 to $9.00 in a report released on Wednesday,Benzinga reports. The brokerage presently has a “sell” rating on the life sciences company’s stock. Citigroup’s price target would indicate a potential downside of 6.53% from the company’s current price.

IART has been the subject of several other research reports. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Integra LifeSciences in a research note on Monday, December 29th. Wall Street Zen lowered shares of Integra LifeSciences from a “buy” rating to a “hold” rating in a report on Saturday. Finally, Wells Fargo & Company lowered their price objective on shares of Integra LifeSciences from $13.00 to $12.00 and set an “equal weight” rating for the company in a research report on Friday, February 27th. Two analysts have rated the stock with a Buy rating, two have given a Hold rating and three have given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Reduce” and a consensus target price of $14.40.

Integra LifeSciences Trading Up 0.8%

IART traded up $0.08 during trading hours on Wednesday, reaching $9.63. The company’s stock had a trading volume of 257,294 shares, compared to its average volume of 751,339. The business’s 50-day moving average is $11.60 and its 200-day moving average is $12.98. The company has a debt-to-equity ratio of 1.66, a current ratio of 2.54 and a quick ratio of 1.46. The stock has a market cap of $750.48 million, a PE ratio of -1.43 and a beta of 1.02. Integra LifeSciences has a fifty-two week low of $9.17 and a fifty-two week high of $24.36.

Integra LifeSciences (NASDAQ:IART) last posted its earnings results on Thursday, February 26th. The life sciences company reported $0.83 EPS for the quarter, beating analysts’ consensus estimates of $0.79 by $0.04. The company had revenue of $434.93 million for the quarter, compared to the consensus estimate of $429.62 million. Integra LifeSciences had a positive return on equity of 14.76% and a negative net margin of 31.58%.The company’s revenue for the quarter was down 1.7% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.97 earnings per share. Integra LifeSciences has set its Q1 2026 guidance at 0.370-0.450 EPS and its FY 2026 guidance at 2.300-2.400 EPS. As a group, equities research analysts predict that Integra LifeSciences will post 2.45 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the business. Allianz Asset Management GmbH boosted its holdings in Integra LifeSciences by 88.7% in the third quarter. Allianz Asset Management GmbH now owns 433,738 shares of the life sciences company’s stock valued at $6,215,000 after purchasing an additional 203,834 shares during the period. Hussman Strategic Advisors Inc. acquired a new stake in Integra LifeSciences in the 3rd quarter valued at about $2,407,000. Systematic Financial Management LP raised its position in Integra LifeSciences by 12.8% in the 2nd quarter. Systematic Financial Management LP now owns 1,056,920 shares of the life sciences company’s stock valued at $12,968,000 after purchasing an additional 120,086 shares in the last quarter. Campbell & CO Investment Adviser LLC purchased a new position in shares of Integra LifeSciences in the 2nd quarter valued at about $632,000. Finally, Edgestream Partners L.P. acquired a new position in shares of Integra LifeSciences during the second quarter worth about $739,000. Institutional investors and hedge funds own 84.78% of the company’s stock.

Integra LifeSciences Company Profile

Integra LifeSciences Corporation is a global medical technology company specializing in products and innovations for neurosurgery, regenerative medicine and reconstructive procedures. The company develops and markets surgical instruments, implants and advanced wound care solutions designed to support tissue repair and functional recovery. Its product portfolio includes collagen-based matrices, dural substitutes, hemostatic agents and specialized spinal and peripheral fixation devices.

Founded in 1989 and headquartered in Plainsboro, New Jersey, Integra has expanded its capabilities through targeted acquisitions and internal research efforts.